|PRODUCT NAME||CATALOG #||UNIT||PRICE||QTY||FAVORITES|
|ABT 263||sc-207241||5 mg||$235.00||
ABT 263 is a novel inhibitor of antiapoptotic BCL-2 proteins and a new promising anticancer drug candidate.
Adams, J., et al.: Science, 281, 1322 (1998), Degterev, A., et al.: Nat. Cell. Biol., 3, 173 (2001), Kitada, S., et al.: J. Med. Chem., 46, 4259 (2003), Danial, N., et al.: Clin. Cancer Res., 13, 7254 (2007),
See how others have used ABT 263. Click on the entry to view the PubMed entry .
PMID: # 28414095
Waetzig, V. et al. 2017. Crosstalk control and limits of physiological c-Jun N-terminal kinase activity for cell viability and neurite stability in differentiated PC12 cells. Mol. Cell. Neurosci.. 82: 12-22.
PMID: # 27030982
García, CP. et al. 2016. Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199. PLoS ONE. 11: e0152607.
PMID: # 24980820
Vasiliauskas, J. et al. 2014. Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model. Oncotarget. 5: 5547-58.
PMID: # 23234544
Sale, MJ. et al. 2013. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. The Biochemical journal. 450: 285-94.
PMID: # 23851982
Kiyota, M. et al. 2013. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Apoptosis : an international journal on programmed cell death. 18: 1437-46.
PMID: # 23012246
Shimura, Y. et al. 2012. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Molecular cancer therapeutics. 11: 2600-9.
PMID: # 22917577
Barrasa, JI. et al. 2012. Resistance to butyrate impairs bile acid-induced apoptosis in human colon adenocarcinoma cells via up-regulation of Bcl-2 and inactivation of Bax. Biochimica et biophysica acta. 1823: 2201-9.
PMID: # 21640157
Sasaki, N. et al. 2011. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Experimental hematology. 39: 817-28.e1.
PMID: # 21424121
Jeong, NY. et al. 2011. The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int. J. Oncol.. 38: 1597-604.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2018 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.